Scalper1 News
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In a press release, J&J touted Alios’ drug candidate for respiratory syncytial virus (RSV), a major cause of lung infections that has no current treatment. The drug, AL-8176, is in midstage clinical Scalper1 News
Scalper1 News